{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:51:19Z","timestamp":1790059879378,"version":"4.0.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":2784,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s13311-015-0401-7","type":"journal-article","created":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T11:49:12Z","timestamp":1448365752000},"page":"96-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Immunotherapy in Peripheral Neuropathies"],"prefix":"10.1016","volume":"13","author":[{"given":"Jean-Marc","family":"L\u00e9ger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Guimar\u00e3es-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Muntean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0401-7_bib1","first-page":"1462","article-title":"Sur un syndrome de radiculo-n\u00e9vrite avec hyperalbuminose du liquide c\u00e9phalo-rachidien sans r\u00e9action cellulaire. Remarques sur les caract\u00e8res cliniques et graphiques des r\u00e9flexes tendineux","volume":"40","author":"Guillain","year":"1916","journal-title":"Bull Soc Med Hop Paris"},{"key":"10.1007\/s13311-015-0401-7_bib2","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.lpm.2013.03.005","article-title":"The discovery of the Guillain-Barr\u00e9 syndrome and related disorders","volume":"42","author":"Hughes","year":"2013","journal-title":"Presse Med"},{"key":"10.1007\/s13311-015-0401-7_bib3","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0401-7_bib4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(10)70041-7","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition","volume":"9","author":"Vallat","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/1756285615575269","article-title":"The pathogenesis of multifocal motor neuropathy and an update on current management options","volume":"8","author":"L\u00e9ger","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-015-0401-7_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11940-010-0065-x","article-title":"Pathogenesis and treatment of anti-MAG neuropathy","volume":"12","author":"Dalakas","year":"2010","journal-title":"Curr Treat Options Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib7","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/brain\/awv054","article-title":"Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia","volume":"138","author":"Miura","year":"2015","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0401-7_bib8","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib9","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.0b013e3181f88345","article-title":"Pain in Guillain-Barr\u00e9 syndrome: a long-term follow-up study","volume":"75","author":"Ruts","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib10","first-page":"1648","article-title":"Fatigue in immune-mediated polyneuropathies","volume":"53","author":"Merkies","year":"1999","journal-title":"European INCAT Group. Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib11","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/j.lpm.2013.02.328","article-title":"Diagnosis, treatment and prognosis of Guillain-Barr\u00e9 syndrome","volume":"42","author":"Van Doorn","year":"2013","journal-title":"Presse Med"},{"key":"10.1007\/s13311-015-0401-7_bib12","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain-Barr\u00e9 syndrome","volume":"35","author":"The Guillain-Barr\u00e9 syndrome Study Group","year":"1985","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.410410304","article-title":"Appropriate number of plasma exchanges in Guillain-Barr\u00e9 syndrome","volume":"41","author":"The French Cooperative Group on Plasma Exchanges in Guillain-Barr\u00e9 syndrome","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome","volume":"326","author":"Van der M\u00e9ch\u00e9","year":"1992","journal-title":"New Engl J Med"},{"key":"10.1007\/s13311-015-0401-7_bib15","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"7","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-015-0401-7_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","author":"Plasma exchange\/Sandoglobulin Guillain-Barr\u00e9 syndrome Trial Group","year":"1997","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0401-7_bib17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effects of methylprednisolone when added to standard treatment with intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome: randomized trial","volume":"363","author":"Van Koningsveld","year":"2004","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0401-7_bib18","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","article-title":"Distinguishing acute-onset CIDP from fluctuating Guillain-Barr\u00e9 syndrome: a prospective study","volume":"74","author":"Ruts","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognosis scoring system for Guillain-Barr\u00e9 syndrome","volume":"6","author":"Van Koningsveld","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr\u00e9 syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/brain\/81.2.157","article-title":"Recurrent polyneuropathies and their corticosteroid treatment","volume":"81","author":"Austin","year":"1958","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0401-7_bib22","first-page":"621","article-title":"Chronic inflammatory polyradiculoneuropathy","volume":"50","author":"Dyck","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"10.1007\/s13311-015-0401-7_bib23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/WCO.0b013e328363bfa4","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: update on clinical features, phenotypes and treatment options","volume":"5","author":"Eftimov","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jns5.12053","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go","volume":"19","author":"Nobile-Orazio","year":"2014","journal-title":"J Peripher Nerv Syst"},{"key":"10.1007\/s13311-015-0401-7_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neurol.2014.06.002","article-title":"Challenges in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"170","author":"Guimar\u00e0es-Costa","year":"2014","journal-title":"Rev Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","article-title":"Incidence and prevalence of CIDP and the association of diabetes mellitus","volume":"73","author":"Laughlin","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ene.12190","article-title":"Epidemiology of chronic inflammatory neuropathies in southeast England","volume":"21","author":"Mahdi-Rogers","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib28","first-page":"617","article-title":"Research criteria for the diagnosis of CIDP","volume":"41","author":"Ad Hoc Subcommittee of the American Academy of Neurology Aids Task Force","year":"1991","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1529-8027.2010.00245.x","volume":"15","author":"Joint Task Force of the EFNS and the PNS","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"10.1007\/s13311-015-0401-7_bib30","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1136\/jnnp.2009.179358","article-title":"Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European Study","volume":"80","author":"Rajabally","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.23794","article-title":"Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy","volume":"73","author":"Querol","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000000205","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"82","author":"Querol","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.61.1.36","article-title":"Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients","volume":"61","author":"Maisonobe","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1529-8027.2010.00251.x","article-title":"A current view of the diagnosis, clinical variants, response to treatment and prognosis in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"15","author":"Viala","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"10.1007\/s13311-015-0401-7_bib35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.23821","article-title":"Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity?","volume":"48","author":"Ayrignac","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0401-7_bib36","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/brain\/awh222","article-title":"Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome","volume":"127","author":"Viala","year":"2004","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0401-7_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mus.22024","article-title":"Response to treatment in patients with Lewis-Sumner syndrome","volume":"44","author":"Attarian","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0401-7_bib38","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1212\/WNL.54.3.615","article-title":"Distal acquired demyelinating symmetric neuropathy","volume":"54","author":"Katz","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib39","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1468-1331.2010.03312.x","article-title":"Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases","volume":"18","author":"Larue","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib40","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/jnnp-2013-306105","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal","volume":"85","author":"Rabin","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003906.pub3","article-title":"Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"8","author":"Mehendiratta","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-015-0401-7_bib42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","article-title":"Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treament","volume":"11","author":"Dyck","year":"1982","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","article-title":"Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial","volume":"9","author":"Van Schaik","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib44","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/WNL.0b013e31824e8f84","article-title":"PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment","volume":"78","author":"Eftimov","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003906.pub3","article-title":"Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"9","author":"Mehndiratta","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-015-0401-7_bib46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0401-7_bib47","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib48","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3181a0fd80","article-title":"Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study","volume":"72","author":"Merkies","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/jns5.12017","article-title":"Efficacy and safety of PrIVIgen(\u00ae) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)","volume":"18","author":"L\u00e9ger","year":"2013","journal-title":"J Peripher Nerv Syst"},{"key":"10.1007\/s13311-015-0401-7_bib50","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"12","author":"Eftimov","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-015-0401-7_bib51","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/jnnp-2013-305644","article-title":"Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects","volume":"85","author":"Rajabally","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib52","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ene.12080","article-title":"Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"20","author":"Markvardsen","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib53","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/ene.12513","article-title":"Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"21","author":"Markvardsen","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib54","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00415-014-7444-2","article-title":"Subcutaneous immunoglobulin in CIDP and MMN : a short-term nationwide study","volume":"261","author":"Cocito","year":"2014","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib55","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib56","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jnnp-2013-307515","article-title":"Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP (IMC study follow-up)","volume":"86","author":"Nobile-Orazio","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib57","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1468-1331.2011.03495.x","article-title":"Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis","volume":"18","author":"Cocito","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","article-title":"Disease modyfing therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines","volume":"58","author":"Goodin","year":"2002","journal-title":"Neurology"},{"issue":"Suppl. 3","key":"10.1007\/s13311-015-0401-7_bib59","first-page":"S23","article-title":"Interferon beta-1a as investigational treatment for CIDP","volume":"60","author":"Vallat","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib60","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0b013e3181d1a862","article-title":"Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"74","author":"Hughes","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib61","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1474-4422(08)70299-0","article-title":"Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study","volume":"8","author":"RMC Trial Group","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib62","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated gycoprotein neuropathy","volume":"80","author":"L\u00e9ger","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib63","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1136\/jnnp.2009.188912","article-title":"Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature","volume":"82","author":"Benedetti","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib64","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-009-5437-3","article-title":"Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy","volume":"257","author":"Marsh","year":"2010","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib65","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000116045","article-title":"Motor neuropathy with proximal multifocal persistent block, fasciculations and myokyma","volume":"25","author":"Roth","year":"1986","journal-title":"Evolution to tetraplegia. Eur Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib66","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1212\/WNL.36.9.1260","article-title":"Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome","volume":"36","author":"Chad","year":"1986","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib67","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.410240113","article-title":"A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside","volume":"24","author":"Pestronk","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib68","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","volume":"15","author":"Van Schaik","year":"2010","journal-title":"J Periph Nervous System"},{"key":"10.1007\/s13311-015-0401-7_bib69","first-page":"2503","article-title":"Multifocal motor neuropathy","volume":"26","author":"Guimar\u00e0es-Costa","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib70","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1212\/WNL.0b013e3181f0738e","article-title":"Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy","volume":"75","author":"Cats","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib71","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1196\/annals.1423.026","article-title":"Efficacy of intravenous immunoglobulin in multifocal motor neuropathy","volume":"1110","author":"L\u00e9ger","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-015-0401-7_bib72","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/mus.21433","article-title":"Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions: report of the AANEM ad hoc committee","volume":"40","author":"Donofrio","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0401-7_bib73","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1212\/WNL.44.3_Part_1.429","article-title":"Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study","volume":"44","author":"Azulay","year":"1994","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib74","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","article-title":"Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study","volume":"59","author":"Van den Berg","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib75","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","article-title":"Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study","volume":"55","author":"Federico","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib76","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","article-title":"Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study","volume":"124","author":"L\u00e9ger","year":"2001","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0401-7_bib77","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","volume":"2","author":"Van Schaik","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-015-0401-7_bib78","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jns5.12046","article-title":"for the IVIg in MMN study. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy","volume":"18","author":"Hahn","year":"2013","journal-title":"J Peripher Nerv Syst"},{"key":"10.1007\/s13311-015-0401-7_bib79","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/brain\/awf193","article-title":"Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment","volume":"125","author":"van den Berg-Vos","year":"2002","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0401-7_bib80","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.WNL.0000110185.23464.A1","article-title":"How long is IVIg effective in multifocal motor neuropathy?","volume":"62","author":"Terenghi","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib81","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/01.WNL.0000140497.85952.FA","article-title":"Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg","volume":"63","author":"Vucic","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib82","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jnnp.2007.121756","article-title":"Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients","volume":"79","author":"L\u00e9ger","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib83","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","article-title":"Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial","volume":"16","author":"Harbo","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib84","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"Eftimov","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"10.1007\/s13311-015-0401-7_bib85","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0b013e3181f735ce","article-title":"Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy","volume":"75","author":"Harbo","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003217.pub4","article-title":"Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy","volume":"4","author":"Umapathi","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-015-0401-7_bib87","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/jnnp.63.6.765","article-title":"Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy","volume":"63","author":"Meucci","year":"1997","journal-title":"J Neurol, Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib88","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/brain\/awm144","article-title":"Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial","volume":"130","author":"Piepers","year":"2007","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0401-7_bib89","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","author":"Fitzpatrick","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"10.1007\/s13311-015-0401-7_bib90","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/(SICI)1097-4598(199801)21:1<55::AID-MUS8>3.0.CO;2-F","article-title":"Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical\/electrophysiological features in 40 cases","volume":"21","author":"Chassande","year":"1998","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0401-7_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002827.pub3","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","volume":"5","author":"Lunn","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-015-0401-7_bib92","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib93","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","article-title":"Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies","volume":"27","author":"Renaud","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0401-7_bib94","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1212\/01.wnl.0000335268.70325.33","article-title":"Long-term effect of rituximab in anti-MAG polyneuropathy","volume":"71","author":"Benedetti","year":"2008","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0401-7_bib95","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp.2008.155325","article-title":"Rituximab for polyneuropathy with IgM monoclonal gammopathy","volume":"80","author":"Niermeijer","year":"2009","journal-title":"J Neurol, Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0401-7_bib96","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0401-7_bib97","doi-asserted-by":"crossref","unstructured":"Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurolog 2006;66:742-744.","DOI":"10.1212\/01.wnl.0000201193.00382.b3"},{"key":"10.1007\/s13311-015-0401-7_bib98","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1529-8027.2011.00343.x","article-title":"Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy","volume":"16","author":"Gruson","year":"2011","journal-title":"J Periph Nerv Syst"},{"key":"10.1007\/s13311-015-0401-7_bib99","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3324\/haematol.2013.087213","article-title":"Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients","volume":"98","author":"Hospital","year":"2013","journal-title":"Hematologica"},{"key":"10.1007\/s13311-015-0401-7_bib100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.nmd.2013.06.006","article-title":"196th ENMC International Workshop: outcome measures in inflammatory peripheral neuropathies 8\u201310 February, Naarden, The Netherlands","volume":"23","author":"Vanhoutte","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-015-0401-7_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.0000000000001044","article-title":"Changing outcome in inflammatory neuropathies. Rasch-comparative responsiveness?","volume":"83","author":"Draak","year":"2014","journal-title":"Neurology"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0401-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0401-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300942X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300942X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0401-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:51:30Z","timestamp":1761807090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792300942X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S187874792300942X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0401-7","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in Peripheral Neuropathies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0401-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}